Advertisement


Lisa A. Carey, MD, and Sherene Loi, MD, PhD, on TNBC: Combination Immune Checkpoint Inhibitor Therapy

ESMO 2018 Congress

Advertisement

Lisa A. Carey, MD, of the University of North Carolina, and Sherene Loi, MD, PhD, of the Peter MacCallum Cancer Centre, discuss the phase III IMpassion 130 trial testing the first-line combination of the PD-L1 inhibitor atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer (Abstract LBA1_PR).



Related Videos

Skin Cancer

Karl Lewis, MD, on Basal Cell Carcinoma: An Ongoing Study

Karl Lewis, MD, of the University of Colorado, discusses a phase II study of cemiplimab in patients with advanced basal cell carcinoma who experienced progression of disease on, or...

Geriatric Oncology
Immunotherapy

Matti S. Aapro, MD, on Immunotherapy in Older Patients

Matti S. Aapro, MD, of the Genolier Cancer Centre, discusses the optimal treatment and supportive care for older patients with cancer, including the importance of maintaining...

Breast Cancer

Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: Research Highlights

Sibylle Lobil, MD, PhD, of the German Breast Group, discusses findings in metastatic breast cancer from the IMpassion130 trial in triple-negative disease and from the PALOMA3 and S...

Hepatobiliary Cancer

Eileen M. O’Reilly, MD, on Hepatobiliary Cancer: Multimodality Approaches

Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses the latest information on locoregional and systemic treatments of hepatocellular carcinoma as well as t...

Bladder Cancer
Kidney Cancer
Immunotherapy

Cora N. Sternberg, MD, on Renal and Bladder Cancers: Focus on Immunotherapy

Cora N. Sternberg, MD, of San Camillo-Forlanini Hospital and the Israel Englander Institute of Precision Medicine at Weill Cornell, discusses results from the phase III CheckMate-0...

Advertisement

Advertisement



Advertisement